Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Postoperative Radiation for Oral Cavity Squamous Cell Carcinoma: The EP The Difference? Album EP Postoperative Radiation for Oral Cavity Squamous Cell Carcinoma • Oral Cavity Cancer is a Surgical Disease • Use Radiation Postoperatively for Appropriate Patients • RT can be used as primary therapy for small (T1, T2) tumors of the oral cavity. • Oral tongue • Floor of Mouth • Lip • Best results are with a combination of external beam radiation and brachytherapy Difficult getting enough dose to primary with brachytherapy while still delivering adequate dose to the regional nodes IJROBP 1990; 18:1287-92. Brachytherapy complications: soft tissue necrosis, osteonecrosis Postoperative Radiation for Oral Cavity Squamous Cell Cancer • • • • • Who needs postop RT? Definite Indications: 1) Positive Margins 2) Multiple Nodes 3) Extracapsular Extension Postoperative Radiation for Oral Cavity Squamous Cell Cancer • • • • • • Who needs postop RT? Less certain indications: 1) Lymphovascular space invasion 2) Perineural spread 3) Single encapsulated node + 4) Thick tumors (Tumors 3-9 mm: 44% node+, 7% local recurrence; >9 mm: 53% subclinical node+, 24% local recurrence Head Neck 2002: 24:513-20) • 5) Surgeon Vibe Postoperative Radiation for Oral Cavity Squamous Cell Cancer • Why give radiation after surgery? • RTOG 73-03: locally advanced H&N cancers: supraglottic larynx, hypopharynx, oral cavity and oropharynx • Preop (50 Gy) vs Postop (60 Gy) • Oral Cavity/oropharynx also had definitive RT arm (65-70 Gy) followed by surgery if residual cancer • Head Neck Surg 1987;10:19-30 Postoperative Radiation for Oral Cavity Squamous Cell Cancer • • • • RTOG 73-03 277 patients Ten year follow-up Improved locoregional control in postoperative RT arm (65%) vs. preop RT (48%, p=0.04) • Trend toward improved survival: 38% vs 33%, p=0.10) • Surgical and radiation therapy complications “similar”. IJROBP 1991;20:21-8. Postoperative Radiation for Oral Cavity Cancer: Radiation Dose • RTOG 7303 established 60 Gy as postop RT dose • MD Anderson performed prospective randomized trial evaluating RT dose for 240 patients with resected stage III/IV cancers of oral cavity, oropharynx, hypopharynx, larynx • 180 cGy fractions • Dose ranged from 52.2 Gy to 68.4 Gy • IJROBP 1993; 26:3-11. Postoperative Radiation for Oral Cavity Cancer: Radiation Dose • Patients receiving <54 Gy had significantly higher failure rate. • No dose response beyond 57.6 Gy except for patients with extracapsular nodal spread. • +ECE needed at least 63 Gy • “Clusters” of two or more of the following also predicted increased risk of failure and need for 63 Gy: oral cavity primary, positive/close margins, nerve invasion, >2 positive nodes, largest node >3 cm, treatment delay >6weeks, Zubrod performance status>2 • Moderate to severe complications seen in 7.1%; more if RT dose >63 Gy • Dose escalation above 63 Gy “does not appear to improve the therapeutic ratio”. Postoperative Radiation for Oral Cavity Cancer: RT + Chemotherapy • Two large randomized trials evaluating RT with or without cisplatin chemotherapy in high-risk resected head and neck squamous cell cancers. • EORTC • RTOG • • NEJM 2004; 350:1945-1952 NEJM 2004: 350:1937-1944 • High risk features: >2 + nodes, +ECE, + margins (EORTC also included perineural spread and vascular tumor embolism) Postoperative Radiation for Oral Cavity Cancer: RT + Chemotherapy • • • • Radiation dose: 60 Gy RTOG; 66 Gy EORTC Cisplatin 100 mg/m2 days 1, 22, 43 both 334 EORTC + 459 RTOG patients (793 total) 26-27% oral cavity primaries • In combined analysis, only patients with +ECE and/or + margins benefited from addition of cisplatin Head Neck 2005; 27: 843-850 Postoperative Radiation for Oral Cavity Cancer: RT + Chemotherapy Postoperative Radiation for Oral Cavity Cancer: RT + Chemotherapy Postoperative Radiation for Oral Cavity Cancer: RT + Chemotherapy • What’s Next? • RTOG 0234 evaluated postop chemoRT (cisplatin or docetaxel) + EGFR inhibitor cetuximab (Erbitux) • This phase II study completed but results are pending Get to Work!! Three-Way Tie for Last